Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories.
atrial fibrillation
bleeding
obesity
oral anticoagulation
stroke
underweight
Journal
JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
24
09
2020
revised:
02
02
2021
accepted:
03
02
2021
pubmed:
5
4
2021
medline:
19
8
2021
entrez:
4
4
2021
Statut:
ppublish
Résumé
This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs. warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories, including ≥40 and <18.5 kg/m Clinical trials have not systematically tested the fixed DOAC dosing in underweight and morbidly obese patients. We retrospectively included consecutive patients with nonvalvular AF with CHA We included 36,094 patients with a mean age of 74 ± 11 years and CHA In patients with nonvalvular AF, DOACs compared to warfarin were associated with better safety and effectiveness across all BMI categories, including underweight and morbidly obese patients.
Sections du résumé
OBJECTIVES
This study sought to evaluate direct oral anticoagulant (DOAC) outcomes (vs. warfarin) in patients with atrial fibrillation (AF) across body mass index (BMI) categories, including ≥40 and <18.5 kg/m
BACKGROUND
Clinical trials have not systematically tested the fixed DOAC dosing in underweight and morbidly obese patients.
METHODS
We retrospectively included consecutive patients with nonvalvular AF with CHA
RESULTS
We included 36,094 patients with a mean age of 74 ± 11 years and CHA
CONCLUSIONS
In patients with nonvalvular AF, DOACs compared to warfarin were associated with better safety and effectiveness across all BMI categories, including underweight and morbidly obese patients.
Identifiants
pubmed: 33812834
pii: S2405-500X(21)00122-5
doi: 10.1016/j.jacep.2021.02.002
pii:
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
649-658Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures Dr. Masri is supported by research grants from Pfizer and Akcea not related to the content of this paper. Dr. Mulukutla receives support for Heart and Vascular Institute Analytics from Boston Scientific not related to the content of the manuscript. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.